CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer

Human Immunology

Volumn 69, Issue 11, 2008, Pages 811-814

  Wang, Rong Fu ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Immune suppression; Regulatory T cells; Tumor immunity; Tumor microenvironment

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 7 RECEPTOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 8;

EID: 57649101649     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.08.276     Document Type: Article

References (62)

1. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
2. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
3. Wang R.F. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 188 (2002) 65-80
4. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8 (2008) 299-308
5. Wang H.Y., and Wang R.F. Regulatory T cells and cancer. Curr Opin Immunol 19 (2007) 217-223
6. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
7. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 299 (2003) 1057-1061
8. Khattri R., Cox T., Yasayko S.A., and Ramsdell F. An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. Nat Immunol 4 (2003) 337-342
9. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol 4 (2003) 330-336
10. - T cells. J Clin Invest 112 (2003) 1437-1443
11. + regulatory T cells and their ligands: implication for immunotherapy. Immunity 20 (2004) 107-118
12. + T reg cells. J Exp Med 203 7 (2006) 1701-1711
13. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 (2006) 1693-1700
14. + gegulatory T cells. J Immunol 174 (2005) 2661-2670
15. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., and Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006) 28-50
16. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182 (2001) 207-214
17. + suppressor T cells. J Clin Invest 114 (2004) 1218-1221
18. Jiang H., and Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 114 (2004) 1198-1208
19. - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 182 (2001) 201-206
20. + T suppressor cells are back to the game: are they players in autoimmunity?. Autoimmun Rev 1 (2002) 279-283
21. Suciu-Foca N., Manavalan J.S., Scotto L., Kim-Schulze S., Galluzzo S., Naiyer A.J., et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 5 (2005) 7-11
22. Suciu-Foca N., and Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248 (2007) 59-67
23. - T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179 (2007) 4323-4334
24. + regulatory T cells mediate immunosuppression in prostate cancer. Clinical Cancer Res 13 (2007) 6947-6958
25. + regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104 (2007) 8029-8034
26. + regulatory thymocytes. Blood 102 (2003) 4107-4114
27. + regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol 180 (2008) 825-832
28. + T cells. IMs. J Immunol 175 (2005) 7093-7097
29. Peng G., Wang H.Y., Peng W., Kiniwa Y., Seo K., and Wang R.-F. Tumor-infiltrating gamma-delta T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27 (2007) 334-348
30. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., and Godfrey D.I. NKT cells-conductors of tumor immunity?. Curr Opin Immunol 14 (2002) 165-171
31. Hayakawa Y., Rovero S., Forni G., and Smyth M.J. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 100 (2003) 9464-9469
32. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 (2003) 267-279
33. Liu K., Idoyaga J., Charalambous A., Fujii S., Bonito A., Mordoh J., et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202 (2005) 1507-1516
34. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515-520
35. Moodycliffe A.M., Nghiem D., Clydesdale G., and Ullrich S.E. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 1 (2000) 521-525
36. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 (2003) 1741-1752
37. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202 (2005) 1627-1633
38. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 (2006) 804-811
39. Piersma S.J., Welters M.J., and van der Burg S.H. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 69 (2008) 241-249
40. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 65 (2005) 1577-1586
41. + regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 104 (2007) 12087-12092
42. + regulatory T cells in human ovarian carcinoma. Cancer Res 65 (2005) 5020-5026
43. + regulatory T cells. J Immunol 177 (2006) 896-904
44. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695
45. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat Rev Immunol 8 (2008) 523-532
46. + regulatory T cells. Immunol Rev 212 (2006) 60-73
47. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28 (2008) 546-558
48. Li M.O., Wan Y.Y., and Flavell R.A. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26 (2007) 579-591
49. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007) 566-569
50. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174 (2005) 1783-1786
51. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., and Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004) 589-601
52. + T cells selectively kill B lymphocytes. Blood 107 (2006) 3925-3932
53. Pandiyan P., Zheng L., Ishihara S., Reed J., and Lenardo M.J. CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4(+) T cells. Nat Immunol 8 (2007) 1353-1362
54. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110 (2007) 1225-1232
55. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., and Erat A. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 (2007) 1257-1265
56. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., and Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 (2005) 582-592
57. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
58. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
59. + regulatory T cell function. Science 309 (2005) 1380-1384
60. + T regulatory cells. J Immunol 175 (2005) 8051-8059
61. Sutmuller R.P., den B.M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116 (2006) 485-494
62. + regulatory T cells. Proc Natl Acad Sci USA 103 (2006) 7048-7053